The Prevalence Of Multi-Comorbid Patients In The US: The Potential For Benefit Being Greater Than Bargained For And The Need For Multi-Indication Value Assessment
Author(s)
Thomas E. Padgett, MSc, PhD1, Geraint Roberts, MChem, PhD1, Marc Evans, MD2, Philip McEwan, BSc, PhD1;
1HEOR Ltd., Cardiff, United Kingdom, 2University Hospital Llandough, Diabetes Resource Centre, Cardiff, United Kingdom
1HEOR Ltd., Cardiff, United Kingdom, 2University Hospital Llandough, Diabetes Resource Centre, Cardiff, United Kingdom
OBJECTIVES: In the US, more than 40% of adults are overweight or obese. There is an interrelationship between obesity, cardiovascular disease (CVD), chronic kidney disease and metabolic diseases referred to as cardiovascular-kidney-metabolic (CKM) syndrome. The objective of this study was to estimate the prevalence of single and multiple CKM comorbidities in the US.
METHODS: We extrapolated contemporary NHANES data (2021-2022), to estimate the US adult population living with one or more CKM comorbidities: obesity, hypertension, dyslipidemia, type 2 diabetes, CVD, poor kidney health, or poor liver health. We estimated the population-level prevalence of each of 128 unique combinations of comorbidities.
RESULTS: An estimated 149 million (59.6%) US adults have one or more CKM comorbidity. Obesity was the most prevalent condition (42.5%), followed by hypertension (24.1%), dyslipidemia (21.8%), T2D (10.6%), CVD (9.1%), poor liver health (3.1%), and poor kidney health (2.7%). The prevalence of multimorbidity was high; overall, 76 million (29.9%) patients had at least two comorbidities of interest and 48.8% of adults with obesity had at least one comorbidity. The most common combinations were obesity with hypertension (4.5%), followed by obesity with hypertension and dyslipidemia (2.8%).
CONCLUSIONS: Where multi-indication treatment effects span multiple distinct, but biologically connected indications, such as GLP-1 RAs, value assessments need to quantify the total benefit experienced by a patient receiving a single therapy.
METHODS: We extrapolated contemporary NHANES data (2021-2022), to estimate the US adult population living with one or more CKM comorbidities: obesity, hypertension, dyslipidemia, type 2 diabetes, CVD, poor kidney health, or poor liver health. We estimated the population-level prevalence of each of 128 unique combinations of comorbidities.
RESULTS: An estimated 149 million (59.6%) US adults have one or more CKM comorbidity. Obesity was the most prevalent condition (42.5%), followed by hypertension (24.1%), dyslipidemia (21.8%), T2D (10.6%), CVD (9.1%), poor liver health (3.1%), and poor kidney health (2.7%). The prevalence of multimorbidity was high; overall, 76 million (29.9%) patients had at least two comorbidities of interest and 48.8% of adults with obesity had at least one comorbidity. The most common combinations were obesity with hypertension (4.5%), followed by obesity with hypertension and dyslipidemia (2.8%).
CONCLUSIONS: Where multi-indication treatment effects span multiple distinct, but biologically connected indications, such as GLP-1 RAs, value assessments need to quantify the total benefit experienced by a patient receiving a single therapy.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE189
Topic
Economic Evaluation
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory), SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Urinary/Kidney Disorders